Liang, H., Ma, D., Xu, Y., Zhao, J., Chen, M., Liu, X., . . . Wang, M. (2019). Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib. Cancer Manag Res.

Liang, Hongge, Di Ma, Yan Xu, Jing Zhao, Minjiang Chen, Xiaoyan Liu, Wei Zhong, Junling Li, và Mengzhao Wang. "Elevated Levels of Pre-treatment Lactate Dehydrogenase Are an Unfavorable Predictor Factor in Patients With EML4-ALK Rearrangement Non-small Cell Lung Cancer Treated With Crizotinib." Cancer Manag Res 2019.

Liang, Hongge, et al. "Elevated Levels of Pre-treatment Lactate Dehydrogenase Are an Unfavorable Predictor Factor in Patients With EML4-ALK Rearrangement Non-small Cell Lung Cancer Treated With Crizotinib." Cancer Manag Res 2019.